Necrólisis epidérmica tóxica en paciente infectado por virus de inmunodeficiencia humana

  • Edinson Enrique Escalante Gómez Estudiante, Programa de Medicina, Universidad del Magdalena, Cartagena, Colombia.
  • Juan David Oliva Martínez Estudiante, Programa de Medicina, Universidad del Magdalena, Cartagena, Colombia.
  • Elicerio Antonio Páez Martínez Estudiante, Programa de Medicina, Universidad del Magdalena, Cartagena, Colombia.
Keywords: Necrólisis epidérmica tóxica, VIH, Fisiopatología, Reacciones cutáneas, Toxic epidermal necrolysis, HIV, Physiopathology, Skin reactions

Abstract

Introduction: Toxic epidermal necrolysis is a multifactorial condition, with the participation, viral infections, drug interactions, and where the genetics plays an important role in susceptibility to adverse reactions. With the presentation of this article is to present the case report of a rare disease in the medical field, but which has a high rate of morbidity and mortality and sequelae. In patients with co-infection with human immunodeficiency virus increases 1000 the risk. We report a 32 year old male with a history of convulsive syndrome in management with phenobarbital and phenytoin, in coinfection human immunodeficiency virus recently diagnosed, no CD4 or viral load and antiretroviral unmanaged, introducing intake of ciprofloxacin 15 days before the start of the clinical picture is consistent with high fever, vesicular lesions Background Erythematosus, Confluent, showing anterior chest wall blebs of watery content, with detachment of the epidermis by exerting gentle pressure on the affected skin leaving Wet Areas Rojas, positive Nikolsky. Extension of the lesions which compromise 91% of her body, accompanied by pruritus of moderate intensity. During the hospital stay therapeutic management is performed with cyclosporine A, and immunoglobulin G specific human antibiotic and antifungal coverage with satisfactory evolution of the patient's hemodynamic status and skin lesions. [Escalante E, Oliva J, Paez E. Toxic epidermal necrolysis in a patients with HIV. Clinical case review. MedUNAB 2012; 15(1):68-72].

Author Biographies

Edinson Enrique Escalante Gómez, Estudiante, Programa de Medicina, Universidad del Magdalena, Cartagena, Colombia.
Juan David Oliva Martínez, Estudiante, Programa de Medicina, Universidad del Magdalena, Cartagena, Colombia.
Elicerio Antonio Páez Martínez, Estudiante, Programa de Medicina, Universidad del Magdalena, Cartagena, Colombia.

References

Roujeau J, Kelly J, Naldi L, rzany B. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. The New England Journal Of Medicine. dec. 14, 1995.

Hernández C, Restrepo R, Mejía M. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. Rev Asoc Colomb Dermatol. 2011;19: 67-75.

Murata J, Abe R. Soluble Fas Ligand: Is It a Critical Mediator of Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome J Invest Dermat. 2007;127:744–5.

Mandal B, Steward M, Singh S. Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: a case report. Age and Ageing 2004; 33: 405–406.

Islam A, Rahman M. Levofloxacin-induced fatal toxic epidermal necrolysis. Ann Pharmacother 2005;39:1136-7.

Whorl S, Loewe R, Pickl WF, Stingl G, Wagner SN. EMPACT syndrome. Dtsch Dermatol Ges. 2005;3:39-43.

Pasricha JS. Corticosteroids in toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol. 2008 Sep-Oct; 74(5):493; author reply 493-5.

Dr. HHF Ho, MBBS(HK), MRCP(UK), FHKCP, FHKAM. Diagnosis and Management of Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. Cheung Sha Wan Dermatological Clinic, Social Hygiene Service, Vol.13 No.10 October 2008.

French LE. Toxic epidermal necrolysis and Stevens Johnson: our current understanding. Allergol Int 2006; 55 (1): 9-16.

Bastuji-Garin S., Rzany B., Stern RS., Shear NH., Naldi L., Roujeau JC. “Clinical classification of cases of toxic epidermal necrolysis, Stevens Johnson Syndrome, and erythema multiforme”. Arch. Dermatol. 1993, 129: 92.

Trent J, Kirsner R, Romanelli P, Kerdel F. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139:39.

Bastuji S, Fouchard N, BertocchiM, Roujeau J, Revuz J, Wolkenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149-53.

Vaishampayan S, Das A, Verma R. SCORTEN: Does it need modification? Indian J Dermatol Venereol Leprol. 2008;74:35-7.

Fritsch PO, Ruiz-Maldonado R. Stevens-Johnson Syndrome-Toxic epidermal necrolysis. Fitzpatrick's dermatology in general medicine. 5th ed. Vol 1. New York : McGraw-Hill; 1999:p 644-54.

Nassif A, Bensussan A, Dorothee G et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118:728–33.

Nori, S. Nebesio, C. Brashear, R. Travers, J. Moxifloxacin-Associated Drug Hypersensitivity Syndrome With Toxic Epidermal Necrolysis and Fulminant Hepatic Failure. Arch Dermatol. 2004;140(12):1537-1538.

Wan Lin Teo, Shiu Ming Pang. Levofloxacin-induced Toxic Epidermal Necrolysis Treated with Intravenous Immunoglobulin. Annals Academy of Medicine Singapore. August 2010, Vol. 39 No. 8.

Livasy CA, Kaplan AM. Ciprofloxacin-induced toxic epidermal necrolysis: a case report. Dermatology. 1997;195(2):173-5. Review. PubMed PMID: 9310730

Moshfeghi M, Mandler HD. Ciprofloxacin induced toxic epidermal necrolysis. Ann Pharmaco Therapy 1993; 27: 1467–9.

Jongen- lavrencic, M. schneeberger, PM. Van Der Hoeven, JG. Ciprofloxacin – induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus. Case report. Infection 31, 2003. N°6.

Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):238-40.

Fernández M, Ruiz Y, Rodríguez J. Toxic epidermal necrolysis, an unusual adverse effect of Capecitabine. Cancer Therapy Vol 6, 271-274, 2008.

Molgó M, Carreño N, Hoyos-Bachiloglu R, Andresen M, González S. Uso de inmunoglobulina humana endovenosa en pacientes con necrólisis epidérmica tóxica y síndrome de sobreposición Stevens Johnson necrólisis tóxica epidérmica. Rev Méd Chile 2009; 137: 383-389.

How to Cite
1.
Escalante Gómez EE, Oliva Martínez JD, Páez Martínez EA. Necrólisis epidérmica tóxica en paciente infectado por virus de inmunodeficiencia humana. MedUNAB [Internet]. 2012 Mar. 31 [cited 2026 Mar. 9];15(1):68-72. Available from: https://revistasunabeduco.biteca.online/index.php/medunab/article/view/1646

Downloads

Download data is not yet available.
Published
2012-03-31

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Escanea para compartir
QR Code
Crossref Cited-by logo

Some similar items: